Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes--a multicentre trial.
D000328:Adult; D000368:Aged; D000721:Ancrod / Q000008:administration & dosage / Q000009:adverse effects*; D012103:Batroxobin / Q000008:administration & dosage / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D004351:Drug Resistance; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000009:adverse effects*; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000401:mortality; D012189:Retrospective Studies; D013917:Thrombin / Q000494:pharmacology; D013923:Thromboembolism / Q000139:chemically induced; D013924:Thrombophlebitis / Q000139:chemically induced
D005343:Fibrinolytic Agents; D005340:Fibrinogen; D010447:Peptide Hydrolases; D000721:Ancrod; D012103:Batroxobin; D013917:Thrombin